

5. Sindrome delirante persistente

Per il presente argomento non sono state identificate revisioni sistematiche di studi randomizzati, pertanto non sono state prodotte tabelle GRADE.
La raccomandazione è stata formulata sulla base della seguente letteratura.

Bibliografia

Hartling L, Abou-Setta AM, Dursun S, Mousavi SS, Pasichnyk D, Newton AS. Antipsychotics in Adults With Schizophrenia: Comparative Effectiveness of First-Generation Versus Second-Generation Medications. *Annals of Internal Medicine* 2012; 157: 498-511.

Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, Samara M, Barbui C, Engel RR, Geddes JR, Kissling W, Stapf MP, Lässig B, Salanti G, Davis JM. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. *Lancet* 2013; 382: 951-962.

Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. *Lancet* 2009; 373: 31–41.

Manschreck TC, Khan NL. Recent advances in the treatment of delusional disorder. *Canadian Journal of Psychiatry* 2006; 51: 114-119.

Munro A, Mok H. An overview of treatment in paranoia/delusional disorder. *Canadian Journal of Psychiatry* 1995; 40: 616-622.

Rathbone J, McMonagle T. Pimozide for schizophrenia or related psychoses. *Cochrane Database of Systematic Reviews* 2007, Issue 3.